ATE388954T1 - Bestimmte substituierte spirocyclische lactame und deren verwendung als pharmazeutika - Google Patents

Bestimmte substituierte spirocyclische lactame und deren verwendung als pharmazeutika

Info

Publication number
ATE388954T1
ATE388954T1 AT04765790T AT04765790T ATE388954T1 AT E388954 T1 ATE388954 T1 AT E388954T1 AT 04765790 T AT04765790 T AT 04765790T AT 04765790 T AT04765790 T AT 04765790T AT E388954 T1 ATE388954 T1 AT E388954T1
Authority
AT
Austria
Prior art keywords
pharmaceuticals
lactames
certain substituted
substituted spirocyclic
spirocyclic
Prior art date
Application number
AT04765790T
Other languages
English (en)
Inventor
Yves Auberson
Ralf Glatthar
Rhys Salter
Oliver Simic
Marina Tintelnot-Blomley
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE388954T1 publication Critical patent/ATE388954T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04765790T 2003-10-03 2004-10-04 Bestimmte substituierte spirocyclische lactame und deren verwendung als pharmazeutika ATE388954T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0323204.8A GB0323204D0 (en) 2003-10-03 2003-10-03 Organic compounds

Publications (1)

Publication Number Publication Date
ATE388954T1 true ATE388954T1 (de) 2008-03-15

Family

ID=29415468

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765790T ATE388954T1 (de) 2003-10-03 2004-10-04 Bestimmte substituierte spirocyclische lactame und deren verwendung als pharmazeutika

Country Status (15)

Country Link
US (2) US20070015781A1 (de)
EP (1) EP1670803B1 (de)
JP (1) JP4549350B2 (de)
CN (1) CN1863804B (de)
AT (1) ATE388954T1 (de)
AU (1) AU2004279553C1 (de)
BR (1) BRPI0415015A (de)
CA (1) CA2540249A1 (de)
DE (1) DE602004012426T2 (de)
ES (1) ES2300815T3 (de)
GB (1) GB0323204D0 (de)
MX (1) MXPA06003645A (de)
PL (1) PL1670803T3 (de)
PT (1) PT1670803E (de)
WO (1) WO2005035535A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050609A1 (en) * 2002-11-27 2004-06-17 Elan Pharmaceutical, Inc. Substituted ureas and carbamates
CA2609562A1 (en) * 2005-06-14 2006-12-28 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
WO2007011810A1 (en) * 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
US7745484B2 (en) * 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
KR101769999B1 (ko) 2008-09-18 2017-08-21 노오쓰웨스턴 유니버시티 Ｎｍｄａ 수용체 조절제 및 그의 용도
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
BR112015018087B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
PE20151436A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
CA2899010A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP6531042B2 (ja) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109661398B (zh) 2016-08-01 2022-07-05 阿普廷伊克斯股份有限公司 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
SG11201900554YA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda modulators and methods of using same
US10918637B2 (en) 2016-08-01 2021-02-16 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
AU2017306152A1 (en) 2016-08-01 2019-01-31 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
BR112019001921A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores do receptor nmda de espiro-lactama e seus usos
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
JP7617043B2 (ja) * 2019-06-24 2025-01-17 ノーレックス インコーポレイテッド ｔｅｒｔ－ブチル（Ｓ）－２－（（２Ｓ，３Ｒ）－１－アミノ－３－ヒドロキシ－１－オキソブタン－２－イル）－１－オキソ－２，５－ジアザスピロ［３．４］オクタン－５－カルボキシレートの固体形態およびそれらを調製する方法
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
EP4608834A1 (de) * 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocyclen enthaltende pyridinverbindungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534520A (en) 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
DK0970957T3 (da) * 1998-06-12 2001-12-03 Hoffmann La Roche Diaza-spiro[3.5]nonan-derivativer
US6613764B1 (en) * 1999-01-06 2003-09-02 The United States Of America As Represented By The Department Of Health And Human Services Aspartic protease inhibitors
WO2002088101A2 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
CN101084240A (zh) * 2004-12-20 2007-12-05 希格马托制药工业公司 MyD88同型二聚体化抑制剂

Also Published As

Publication number Publication date
HK1092472A1 (en) 2007-02-09
DE602004012426D1 (de) 2008-04-24
US20070015781A1 (en) 2007-01-18
CN1863804A (zh) 2006-11-15
CA2540249A1 (en) 2005-04-21
ES2300815T3 (es) 2008-06-16
GB0323204D0 (en) 2003-11-05
AU2004279553B2 (en) 2009-03-12
PL1670803T3 (pl) 2008-08-29
PT1670803E (pt) 2008-04-23
JP2007509038A (ja) 2007-04-12
EP1670803A1 (de) 2006-06-21
AU2004279553C1 (en) 2009-07-23
MXPA06003645A (es) 2006-06-05
BRPI0415015A (pt) 2006-11-07
WO2005035535A1 (en) 2005-04-21
DE602004012426T2 (de) 2009-03-26
CN1863804B (zh) 2010-05-26
JP4549350B2 (ja) 2010-09-22
US7655686B2 (en) 2010-02-02
EP1670803B1 (de) 2008-03-12
AU2004279553A1 (en) 2005-04-21
US20070265328A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
ATE388954T1 (de) Bestimmte substituierte spirocyclische lactame und deren verwendung als pharmazeutika
ATE435210T1 (de) Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten
SE0202133D0 (sv) Novel compounds
ATE496884T1 (de) Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste
ATE547395T1 (de) Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
GEP20084329B (en) 5,7-diaminopyrazolo [4,3-d] pyrimidines useful in the treatment of hypertension
DE602005013248D1 (de) Amidderivate von 3-phenyldihydropyrimidoä4,5-düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel
DE602004001857D1 (de) Thienopyrimidindione und deren verwendung bei der modulierung von autoimmunerkrankungen
ATE469892T1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
BR0315547A (pt) Derivados de quinolina como antagonistas de crth2
ATE448225T1 (de) Aza-bicycloalkylether und deren verwendung als alpha7-nachr agonisten
SE0302116D0 (sv) Novel compounds
SE0302139D0 (sv) Novel compounds
NO20063355L (no) Nye trisykliske spiroderivater som modulatorer for kemokinreseptoraktivitet
MY142474A (en) 1h-quinazoline-2,4-diones
ATE383345T1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.
DE60327375D1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
DE69920455D1 (de) Bis-indolederivate und ihre verwendung als entzündungshemmende mittel
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
SE0303090D0 (sv) Novel compounds
TW200740781A (en) Novel compounds
UA80814C2 (en) Heterocyclic oxime compounds, a process for their preparation (variants) and pharmaceutical compositions containing them, intermediate
DK1730144T3 (da) Substituerede 1,4,8-triazaspiro[4.5]decan-2-on-forbindelser

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1670803

Country of ref document: EP

REN Ceased due to non-payment of the annual fee